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Should we welcome food industry funding of public
health research?
Researchers should accept research grants from the food industry, write Paul Aveyard and Derek
Yach, but Anna B Gilmore and Simon Capewell say that it biases science
Paul Aveyard professor of behavioural medicine 1, Derek Yach executive director 2, Anna B Gilmore
professor of public health 3, Simon Capewell professor of public health and policy 4
1Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG; 2Vitality Institute, New York, USA; 3UK Centre for
Tobacco and Alcohol Studies, University of Bath, Bath, UK; 4Department of Public Health and Policy, University of Liverpool, UK
Yes—Paul Aveyard, Derek Yach
The food industry consists of farmers, manufacturers,
wholesalers, retailers, distributors, and the catering industry. If
it disappeared tomorrow, most people in the developed world
would die within months. It is a major employer; more people
are employed in the food industry in the UK, for example, than
any other manufacturing sector.1 For these reasons, government
policies seek to support the industry. From this perspective, it
would be absurd for health policy researchers to shun
collaborating with the food industry.
Of course, our aims are not always allied. Many elements of
the industry promote and sell food that undermines health.When
faced with effective public health actions to curtail consumption
of unhealthy products it sometimes fights against the cause of
public health. Therefore not all cooperation is appropriate. For
example, although industry’s views are critical to developing
public policy, its presence when such policy is decided is
inappropriate.
But workingwith the food industry inevitably involves accepting
its funding, in kind at least. Take the FLICC study,2 in which a
supermarket searched its database to find regular consumers of
processed food, often high in saturated fat and salt, and asked
them to participate in the trial. The trial is testing an intervention
to promote the motivation and capacity of shoppers to make
better use of front-of-pack “traffic light” nutrient labels and uses
loyalty card data to determine the nutritional profile of
purchases. The retailer paid the costs of its staff’s time used for
discussion with researchers and to collect and process loyalty
card data. Would the study be better if the researchers had paid
the supermarket for their time and information? We doubt
anyone would seriously argue so, bearing in mind this would
remove funding from other worthy research.
Reputational advantage
Why might the supermarket co-fund this study? It is because
supermarket managers share the goals and values of the
researchers. There is no reason they should prefer to sell less
healthy food over healthier food. It may offer reputational
advantage to help shoppers to make healthier choices. Only the
most cynical would argue that collaborating in this way is
pretending to do the right thing and merely deflects radical and
unpalatable options, such as regulation.
In some cases, the interests of the food industry align so strongly
with those of health researchers that industry is willing to pay
the entire costs of the study. Basic research on better ways to
reduce salt, sugar, and fat; intervention research on the benefits
of micronutrients to health; or research on the effect of
discounting healthy food on dietary patterns are examples.
Leading manufacturers are investing billions of dollars to
improve the nutritional quality of their products—well in excess
of public research investment.
Strong safeguards
Independent researchers should be responsible for design,
conduct, and analysis of the research and not the company. This
implies research organisations accept direct payments from the
food industry. Such payments require strong safeguards to avoid
bias and the appearance of bias: researchers should have no
commercial interest in the product; payments should be made
to the organisation not the researchers and should reflect the
cost of the research to avoid researchers feeling beholden to the
company; the analysis should be done by statisticians
independent of the investigators who designed and conducted
the study; and researchers should publish the results regardless
of the outcome. There are excellent examples of best practice
in industry funded food research3 4 and other contested academic
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areas.5-7 The alternatives are that the research is not done, that
it is done by the company itself, or that the public pays.
In many cases food industry and health goals clearly align and
co-funding in kind or through direct payment from industry is
appropriate. Examples of bad practice do not invalidate findings
from appropriate collaborations. Providing safeguards are in
place, no reasonable person should doubt the integrity of
collaborative research.
No—Anna B Gilmore, Simon Capewell
Corporations are legally required to maximise shareholder
profits and therefore have to oppose public health policies that
could threaten profits. Unequivocal, longstanding evidence
shows that, to achieve this, diverse industries with products that
can damage health have worked systematically to subvert the
scientific process. The research they fund produces uniquely
favourable outcomes.8-11 Internal documents show how they
manipulate evidence in their favour, strategically communicate
that evidence to influence public and political opinion, and
ultimately minimise regulation and legal liability.8-13
The food industry is diverse, but there is a clear conflict between
public health and companies that produce ultraprocessed food
and sugary soft drinks. It is unsurprising, therefore, that similar
evidence is now emerging for these companies. Studies they
fund are generally biased in their favour.14 15 Previously secret
documentation shows they are working to ensure research and
researchers they fund deflect attention from their products and
unwanted regulatory interventions.16 17 They promote weak or
ineffective interventions aimed at individuals rather than
upstream population level regulation, and emphasise physical
activity and energy balance to the exclusion of diet based drivers
of obesity, messaging reinforced by non-governmental
organisations fronted by industry funded scientists.16
Four flawed excuses
Much like the case with tobacco, scientists taking money from
ultraprocessed food companies typically offer four flawed
excuses.
“I am an objective, impartial scientist and cannot
be biased”
Wrong. Industry funded research is significantly more likely to
produce outcomes favourable to that industry (rates vary from
about five14 to 888 times). Sometimes researchers are willing to
fabricate data or allow corporate lawyers to hide unfavourable
studies.8 But even well meaning scientists are (often
subconsciously) biased, even by small gifts.18 19
“I control the data and have freedom to publish,
so my research cannot possibly advantage
industry”
Wrong. Extensive evidence shows that quality, peer reviewed
studies where scientists control the data and are free to publish
are vital to corporate strategies.8 13 Industry funds these studies,
often by the top researchers in the top institutions, because it
knows they are safe (that is, the results will not threaten industry
interests), will divert attention to alternative risk factors, enhance
industry reputation, and create a cadre of indebted experts.8-20
These scientists may be doing quality work but it does not
advance science. Instead it puts industry in control of the
research agenda. By determining what questions are asked and
, crucially, not asked, industry can distort the evidence base to
defend itself from attack.13
“Industry funds are crucial for research”
Wrong. Industry funding accounts for a surprisingly small
proportion of total research funding, less than one tenth in the
UK or US.21
“Disclosure and peer review provide sufficient
redress”
These are essential and do help, but are insufficient.20
Experimental studies show disclosure can, paradoxically,
exacerbate rather than reduce the biasing effect of conflicts of
interest.22 Moreover, conflicts of interest may not be identified
as relevant, particularly when industry is deliberately funding
distracting research, and even the best peer review can fall short.
What can be done?
We must not allow the food industry and its allies to use these
smokescreens (such as limited industry collaboration in
independently funded studies) to obfuscate and delay action on
the key issue in this debate—the funding of obesity related
research by corporations whose interests are threatened by
effective anti-obesity interventions. Until funding models
change, our ability to counter the obesity epidemic will be
seriously constrained. We therefore need more radical funding
models that allow corporations to fund research while protecting
that research from their influence.
Previous work shows that dedicated manufacturer taxes, licence
fees, or legally mandated contributions (with the funds raised
then administered independently from industry) are most likely
to maximise transparency and minimise conflicts of interest.23
Funding of research through a tax on tobacco and alcohol in
California and Thailand shows that this approach is feasible.
Change will not occur until public health researchers refuse to
take money from the ultraprocessed food industry. It worked
for tobacco; in the early 1990s all bar one UK medical school
took tobacco industry funding. That is unthinkable today, and
the change has underpinned progress in tobacco control.
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